Replies to post #688 on Progenics Pharmaceuticals Inc. (PGNX)

[vinmantoo]

Ron,

I feel pretty good about approval so will let it ride. Relistor sales are spiking up and there is the 1404 prostate cancer imaging agent phase III trial data coming late in around October so PGNX isn't a one-trick pony. However, if the price rises to over $10 before the FDA rules, I might sell 5%-10% of my shares for a bit of insurance.

I believe I read that Azedra is a $200 million market and PGNX has a market cap of only $550 million.